Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$382.47
-2.2%		$400.14
$269.77
▼
$447.03
$206.78B0.432.72 million shs3.35 million shs
Biogen Inc. stock logo
BIIB
Biogen
$215.43
+2.2%		$209.57
$135.39
▼
$225.80
$31.83B0.171.21 million shs928,511 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.48%-11.65%-6.22%+10.51%+39.75%
Biogen Inc. stock logo
BIIB
Biogen
-0.83%-5.36%+1.74%+5.39%+46.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$382.47
-2.2%		$400.14
$269.77
▼
$447.03
$206.78B0.432.72 million shs3.35 million shs
Biogen Inc. stock logo
BIIB
Biogen
$215.43
+2.2%		$209.57
$135.39
▼
$225.80
$31.83B0.171.21 million shs928,511 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.48%-11.65%-6.22%+10.51%+39.75%
Biogen Inc. stock logo
BIIB
Biogen
-0.83%-5.36%+1.74%+5.39%+46.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.33
Hold$381.68-0.21% Downside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$230.146.83% Upside

Current Analyst Ratings Breakdown

Latest AMGN and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$242.00
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetReduce$165.00 ➝ $175.00
9/10/2026
Amgen Inc. stock logo
AMGN
Amgen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$445.00 ➝ $425.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$450.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$400.00
9/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$400.00 ➝ $435.00
9/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$225.00 ➝ $245.00
8/25/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$240.00 ➝ $260.00
8/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$427.00 ➝ $457.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$362.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$375.00 ➝ $460.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$38.10B5.43$32.89 per share11.63$16.08 per share23.79
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.17$22.94 per share9.39$124.45 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0923.7715.682.8322.95%124.14%13.18%11/3/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6538.1313.372.358.32%11.18%6.88%10/29/2026 (Estimated)

Latest AMGN and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.64%+8.27%62.65%14 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A

Latest AMGN and BIIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Biogen Inc. stock logo
BIIB
Biogen
87.93%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable

Recent News About These Companies

Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 9 at 4:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944444-biogen-inc-biib-presents-at-wells-fargo-21st-annual-healthcare-conference-transcript
California State Teachers Retirement System Has $10.27 Billion Position in Biogen Inc. $BIIB
September 9 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-1027-billion-position-in-biogen-inc-biib-2026-09-09/
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
September 8 at 2:31 PM  |  finance.yahoo.comhttps://finance.yahoo.com/technology/articles/register-now-limited-seating-remains-143000671.html
Lilly Builds Neuroscience into a New Long-Term Growth Driver
September 8 at 9:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/2986190/lilly-builds-neuroscience-into-a-new-long-term-growth-driver?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2986190
Lilly Builds Neuroscience into a New Long-Term Growth Driver
September 8 at 9:30 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lilly-builds-neuroscience-long-term-122700438.html
Saudi Central Bank Increases Stock Holdings in Biogen Inc. $BIIB
September 8 at 5:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-saudi-central-bank-increases-stock-holdings-in-biogen-inc-biib-2026-09-08/
Amundi Purchases 726,004 Shares of Biogen Inc. $BIIB
September 8 at 3:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-purchases-726004-shares-of-biogen-inc-biib-2026-09-08/
Stoke and Biogen report durable seizure reductions with zorevunersen at four years
September 7 at 1:45 PM  |  thepharmaletter.comT
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
September 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/exelixis-exel-13-3-since-153006855.html
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
September 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/m/eaac730d-29cf-3d81-a48f-e7a16642c09d/this-biotech-wins-a-big-fda.html
Nykredit A S Takes Position in Biogen Inc. $BIIB
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-takes-position-in-biogen-inc-biib-2026-09-06/
B. Metzler seel. Sohn & Co. AG Cuts Stake in Biogen Inc. $BIIB
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-cuts-stake-in-biogen-inc-biib-2026-09-05/
Stoke And Biogen Unveil Long-Term Zorevunersen Data In Dravet Syndrome
September 4, 2026  |  rttnews.comhttps://www.rttnews.com/3688494/stoke-and-biogen-unveil-long-term-zorevunersen-data-in-dravet-syndrome.aspx
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000907.html
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-present-long-233000592.html
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 3, 2026  |  financialpost.comF
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356336/0/en/stoke-therapeutics-and-biogen-present-long-term-clinical-data-that-support-the-disease-modifying-potential-of-zorevunersen-an-investigational-medicine-for-the-treatment-of-dravet-s.html
China approves at-home SC formulation of Leqembi for early Alzheimer's
September 3, 2026  |  thepharmaletter.comT
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biogen-biib-brings-home-weekly-110629509.html
Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688074/biogen-and-eisai-announce-china-approval-for-subcutaneous-leqembi-to-treat-early-alzheimer-s-disease.aspx
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/biogen-biib-stock-could-48-032559262.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$382.47 -8.80 (-2.25%)
Closing price 04:00 PM Eastern
Extended Trading
$383.52 +1.05 (+0.28%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$215.43 +4.70 (+2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$215.50 +0.07 (+0.03%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas